Skip to content

GlobalLawDBby GenieAI

Laws Search Sanctions Map Data Developers

Search the text of the law

Log in Get an API key

Laws Search Sanctions Map Data Developers

Log in Get an API key

The Global Law Database. Free to read, built for people and AI agents.

Explore

All laws
Search the text
Sanctions
Map of connections
Compare UK and EU

Developers

AI agents (MCP)
REST API
Bulk data
API keys

Coverage

United Kingdom
European Union
United States
Canada
Australia
France
Germany
Netherlands
Spain
Austria
Norway
Finland
Switzerland
Ireland

GlobalLawDB is made by GenieAI, London. It is not legal advice: check the official text before relying on it. Text comes from official publishers under their licences, listed on the Data page.

ThemeMatch my systemLightDark

European Union
Olainfarm AS v Latvijas Republikas Veselības ministrija and Zāļu valsts aģentūra (C-104/13)
Judgment
Consideration of the questions referred
Question 1
35

Olainfarm AS v Latvijas Republikas Veselības ministrija and Zāļu valsts aģentūra (C-104/13)

Judgment of 23 Oct 2014law://eu/cjeu/2013/c-104-13/para_35@2026-11-11

35However, Article 47 of the Charter of Fundamental Rights of the European Union (‘the Charter’) provides that any person whose rights guaranteed by the law of the European Union are violated has the right to an effective remedy before a tribunal.

Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.

Key facts

Court: Court of Justice · Fifth Chamber
Case: C-104/13 · ECLI:EU:C:2014:2316
Decided: 23 Oct 2014
Procedure: Preliminary reference · referred by the Augstākās Tiesas Senāts (Latvia)
Applicant: Olainfarm AS
Defendants: Latvijas Republikas Veselības ministrija; Zāļu valsts aģentūra
Rapporteur: D. Šváby
Advocate General: N. Wahl
Bench: 5 judges
T. von Danwitz, C. Vajda, A. Rosas, E. Juhász, D. Šváby
Language: Latvian
Official: CURIA · EUR-Lex 62013CJ0104

Topics

Pharmaceutical and cosmetic products

History · 1 version

23 Oct 2014Reading

Connections

Interprets 2: Charter of Fundamental Rights of the European Union (consolidated 2016)2 provisions; Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use
Cited by 9: EG Labo Laboratoires Eurogenerics SAS and Theramex France SAS v Agence nationale de sécurité du médicament et des produits de santé (ANSM) and Biogaran SAS (C-118/24)3 provisions; Orion Oyj v European Commission (T-223/20); Mylan IRE Healthcare Ltd v European Commission (T-303/16); Pharmaceutical Works Polpharma S.A. v European Medicines Agency (T-611/18); Staat der Nederlanden v Warner-Lambert Company LLC (C-423/17); Proceedings brought by Astellas Pharma GmbH (C-557/16)5 provisions; Pari Pharma GmbH v European Medicines Agency (T-235/15)2 provisions; PP Nature-Balance Lizenz GmbH v European Commission (C-82/15); Novartis Europharm Ltd v European Commission (T-472/12)
Cites 7: Charter of Fundamental Rights of the European Union (consolidated 2016); Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use; Nancy Fern Olivieri v Commission of the European Communities and European Agency for the Evaluation of Medicinal Products (T-326/99); The Queen v Licensing Authority of the Department of Health and Norgine Ltd, ex parte Scotia Pharmaceuticals Ltd (C-440/93); Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use (Text with EEA relevance); Olainfarm AS v Latvijas Republikas Veselības ministrija and Zāļu valsts aģentūra (C-104/13); The Queen, on the application of Generics (UK) Ltd v Licensing Authority (C-527/07)